Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

HackerRank is a pretty cool place to get better at coding. It’s got tons of challenges that really make you think and figure things out faster. Whether you’re just starting out or you’ve been coding ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Ever wonder how some folks just seem to breeze through coding challenges and land those awesome tech jobs? A lot of it comes down to practice, and platforms like HackerRank are super helpful for that.

Looking to refresh your stock of “Never Have I Ever” questions? It’s always good to go into a game with a lot of Qs lined up. That way, you don’t have to think of them under pressure, especially if ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...